Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share. The offering price reflects the Oct. 24 closing price. The company expects to raise approximately $3.4 million in gross proceeds before deducting placement agent fees and other offering expenses.
The offering is being led by H.C. Wainwright & Co. as the exclusive placement agent. Notably, the offering includes participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini, demonstrating insider confidence in the company’s pipeline. Closing is expected on or about Oct. 28, 2025, subject to customary closing conditions. Net proceeds are earmarked for working capital and general corporate purposes.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow on LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. For the full press release, visit https://ibn.fm/d1q9Q.
This offering provides Annovis with additional capital to advance its pipeline of therapies targeting Alzheimer’s and Parkinson’s diseases, which represent significant unmet medical needs. The participation of company insiders underscores their belief in the potential of Annovis’s drug platform. The funds will be used to support ongoing research and development activities as the company progresses toward key clinical milestones.
